OncoBeta receives ethics approval for EPIC-Skin study to evaluate Rhenium-SCT in Australia

/PRNewswire/ -- OncoBeta® GmbH, a medical device company specialized in innovative epidermal radioisotope therapies announced today that the company has...

Related Keywords

Germany ,New York ,United States ,Australia ,North Sydney ,New South Wales ,Munich ,Bayern ,Sydney ,United Kingdom ,Garching ,Austria ,Australian ,Saima Vohra ,Gerhard Dahlhoff ,Shannond Brown ,Oncobeta Gmb ,Therapeutic Nuclear Medicine ,Instagram ,National Health ,Linkedin ,Clinical Research Organization ,Facebook ,Research Council ,Therapeutic Goods Administration ,Medical Research Council ,Complete Response Rate ,Skin Study ,Personalised Irradiation ,Medical Director ,Safety Monitoring ,Clinical Trials ,Managing Director ,Oncobeta Australia ,Patient Reported Outcome Measures ,Royal North Shore Hospital ,Skin Cancer Therapy ,Basal Cell Carcinomas ,Squamous Cell Carcinomas ,Risk Factors ,Radionuclide Therapy ,Squamous Cell ,Oncobeta Gmbh ,